Market
Will Novo Nordisk announce a new Phase 3 trial for CagriSema by end of 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Novo Nordisk or reputable financial news outlets
Story
Novo Nordisk Shares Drop 27% After CagriSema's 22.7% Weight Loss Misses Target
Dec 20, 2024, 11:46 AM
Novo Nordisk's shares plummeted by up to 27%, the most significant drop since April 2002, after the company's experimental obesity drug CagriSema failed to meet weight-loss expectations in a pivotal Phase 3 trial. The REDEFINE 1 trial demonstrated that patients receiving CagriSema achieved an average weight loss of 22.7% after 68 weeks, falling short of the anticipated 25% target. The company's market capitalization shrank by over 1,000 billion kroner. The disappointing results have raised concerns about Novo Nordisk's ability to compete in the rapidly growing weight-loss market, particularly against rivals like Eli Lilly and Viking Therapeutics. Eli Lilly's shares surged, while Viking Therapeutics' shares also rose on the news. Additionally, only 57% of patients in the trial reached the highest dose of CagriSema, prompting questions about the drug's tolerability. The Danish krone declined amid worries about the potential impact on Denmark's economy.
View original story
Similar markets
Yes • 50%
No • 50%
Develop a new obesity drug • 25%
Increase investment in marketing existing drugs • 25%
Pursue mergers or acquisitions • 25%
Focus on improving CagriSema • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Discontinue development • 25%
Partner with another company • 25%
Seek further trials • 25%
Submit for regulatory approval • 25%
No • 50%
Yes • 50%
Weight loss > 20.7% • 25%
Weight loss between 19% and 20.7% • 25%
Weight loss between 17.5% and 19% • 25%
Weight loss < 17.5% • 25%
Safety label update • 25%
No action taken • 25%
Product recall • 25%
Other regulatory actions • 25%
Trial cancelled • 25%
Meets expectations • 25%
Exceeds expectations • 25%
Falls short of expectations • 25%
